创新药物风险投资策略现状研究  

Current strategy of venture investment on innovative drug

作　　者：武霞 柯朝静 邵蓉[1] WU Xia;KE Chao-jing;SHAO Rong(The Research Center of National Drug Policy&Ecosystem,China Pharmaceutical University,Nanjing 211198,China;China State Institute of Pharmaceutical Industry,Shanghai 201203,China)

机构地区：[1]中国药科大学国家药物政策与医药产业经济研究中心,南京211198 [2]中国医药工业研究总院,上海201203

出　　处：《中国新药杂志》2020年第21期2459-2464,共6页Chinese Journal of New Drugs

摘　　要：风险投资是创新药研发获得资本的主要途径之一,创新药研发门槛较高,研究药物研发投资策略可以进一步激励和吸引风险投资进入药物研发领域,促进新药成果转化。在风险投资决策的评估阶段,风险资本家采用一定的投资决策准则判断投资项目的风险和预期的收益。本研究基于文献统计法分析了近年来创新药风险投资价值评估体系的发展概述、研究热点等,在国内外风险投资价值评估理论的基础上,结合创新药物特色,提出当前对创新药物评估体系产生影响的关键因素,为新药投资决策的进一步研究提供参考。Venture investment is one of the major pathways to obtain capital for innovative drug research and development. Since the threshold of innovative drug research and development is relatively high,research on investment strategy of drug research and development will further stimulate and attract venture capital to enter this field,promoting the transformation of innovative drug achievements. In the evaluation stage of venture capital decision,venture capitalists apply certain investment decision criterias to judge the risks and expected returns of investment projects. This article analyzes recent years’ innovative drug value evaluation system of venture capital development overview and research hot spots,etc.,using statistics analysis method. Based on the domestic and foreign risk investment value assessment theory,combined with the characteristics of innovative drugs,this article puts forward the current impact of the key factors on drug innovation evaluation system,hoping for providing reference for the further study of the investment decisions on innovative drugs.

关 键 词：创新药 风险投资 评估机制 策略 文献分析 

分 类 号：R95[医药卫生—药学]